Herzog H, Spohr G, Notohamiprodjo G, Feinendegen L E
Nucl Med Commun. 1987 Mar;8(3):157-75. doi: 10.1097/00006231-198703000-00006.
Estimates of the radiation dose resulting from liver-spleen scintigraphy 99Tcm-labelled colloids are based on pharmacokinetic data mainly determined in animals. The aim of this study was to check the pharmacokinetic data by direct, absolute in vivo quantification in man. For this purpose appropriate methods of measurement were developed, or procedures taken over from literature were modified. Liver and spleen activities were directly measured using a double-energy window technique. Activities in other organs were quantified by conjugate whole-body scans. All measurement procedures were checked using the whole-body Alderson phantom. Pharmacokinetic data for sulphur colloid, tin colloid, human serum albumin (HSA) millimicrospheres, and phytate were obtained in 13 to 20 normal subjects for each type of colloid. Depending on the colloid type liver uptake was between 54 and 75% of the total administered dose (TAD) and spleen uptake was 3.5 to 21% TAD. Activity measured in blood, urine, lung and thyroid proved to be far from negligible. The results of this work suggest a correction of the animal-based data of colloid distribution and radiation dose on the basis of the direct measurement of absolute uptake in man.
99锝标记胶体肝脾闪烁扫描术所致辐射剂量的估计值主要基于在动物身上确定的药代动力学数据。本研究的目的是通过对人体进行直接、绝对的体内定量来检验药代动力学数据。为此,开发了合适的测量方法,或对文献中的方法进行了修改。使用双能窗技术直接测量肝脏和脾脏的活性。通过共轭全身扫描对其他器官的活性进行定量。所有测量程序均使用全身Alderson体模进行检验。对于每种胶体类型,在13至20名正常受试者中获得了硫胶体、锡胶体、人血清白蛋白(HSA)毫微球和植酸盐的药代动力学数据。根据胶体类型的不同,肝脏摄取量占总给药剂量(TAD)的54%至75%,脾脏摄取量为TAD的3.5%至21%。在血液、尿液、肺部和甲状腺中测得的活性远非可以忽略不计。这项工作的结果表明,应根据对人体绝对摄取量的直接测量,对基于动物的胶体分布和辐射剂量数据进行校正。